Pure Biologics

What Pure Biologics does

Pure Biologics S.A. is a Polish clinical-stage biotechnology company headquartered in Wrocław, Poland, developing novel immunooncology therapies using proprietary antibody and aptamer technologies. The company is positioned as the first entity in Poland focused on the development of completely new, non-generic, non-biosimilar biological drugs based on antibodies — a category the company frames as a leading trend in the global pharmaceutical industry. Its therapeutic portfolio consists of three named candidates: PBA-0405 (a cancer treatment candidate that has successfully completed a Phase 0 study), PB004 (an immunooncology candidate with FDA Phase 0 approval and first administration completed, supported by a partnership agreement), and PB003G (an immunooncology candidate with FDA Phase 0 approval, also under partnership). The underlying technology platform centers on in vitro selection methodologies for antibodies and aptamers to develop molecules with therapeutic potential in oncology.

The company is pre-revenue and pre-commercial, with 51-100 employees and no products on the market. Its business model relies on advancing internal candidates through clinical milestones, securing co-development partnerships for specific assets, and attracting non-dilutive funding (including EU-funded projects) to extend R&D runway. Future revenue is expected to flow through standard pharmaceutical commercialization channels following regulatory approvals, with no pricing publicly disclosed at this stage. The company is led by CEO and founder Filip Jeleń, maintains a bilingual (English/Polish) corporate and investor-relations web presence, and operates with public-company-style reporting infrastructure (current reports, periodic reports, general meetings, prospectuses) despite being classified as private. Cumulative disclosed funding to date includes approximately $7.4M raised in August 2019 from undisclosed investors. Note: the company history data lists 2020 for most milestones while firmographic data lists a founding year of 2010; the discrepancy suggests possible reincorporation or data aggregation timing differences.

Name

Pure Biologics

Legal name

Pure Biologics S.A.

Website

https://purebiologics.pl

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Pure Biologics S.A. is a Polish clinical-stage biotechnology company developing novel immunooncology therapies based on proprietary antibody and aptamer in vitro selection platforms, with three candidates advancing through Phase 0 clinical trials.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Therapeutic antibodies
• Aptamer technology
• Immunooncology drugs
• Biological drug development
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Wroclaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Marketing channels2 records

Core offering

Pure Biologics is a clinical-stage biopharmaceutical company that develops novel, non-generic, and non-biosimilar biological drugs based on proprietary antibody and aptamer technologies for immunooncology applications. Its therapeutic portfolio comprises three named candidates (PBA-0405, PB004, PB003G) advancing through Phase 0 clinical trials for cancer treatment.

Product overview

Pure Biologics is a biotechnology company developing a therapeutic portfolio focused on immunooncology therapies using antibody technologies. The company is developing new, non-generic and non-biosimilar biological drugs based on antibodies. Their pipeline includes three named therapeutic candidates: PBA-0405 (cancer treatment, Phase 0 completed), PB004 (Phase 0 clinical trial with partnership agreement), and PB003G (Phase 0 clinical trial with partnership agreement). The company also explores aptamer technologies alongside antibody platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• PBA-0405
• PB004
• PB003G

Quantifiable outcome

• Successful completion of Phase 0 study for PBA-0405 in cancer treatment
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Not specifically named in available source materialcoreOthersPure Biologics has a partnership agreement for PB004 and PB003G projects, though specific partner names are not disclosed in the home page content. The company participates in EU-funded projects as indicated by image references on the website.

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Direct peers

• Molecular Partners: Swiss clinical-stage biotech developing DARPin-based therapeutic candidates (alternative scaffold to antibodies/aptamers) in oncology. Comparable as a small European biotech using proprietary non-antibody scaffolds for cancer therapeutics.
• F-star Therapeutics: Clinical-stage biotech developing bispecific antibody therapeutics for cancer using a proprietary modular antibody platform. Directly comparable as a small biotech with proprietary antibody engineering technology for immuno-oncology.
• CytomX Therapeutics: Clinical-stage oncology biotech developing conditionally activated antibody therapeutics (Probody platform). Comparable in approach of engineering novel antibody formats for cancer with multiple clinical-stage candidates.
• Philogen: Italian-Swiss biotech developing antibody-based therapeutics for cancer and inflammatory diseases. Closely comparable in size, stage, geography (European), and antibody-oncology focus.
• Macrogenics: Clinical-stage biotech developing antibody-based therapeutics for cancer using proprietary Fc engineering and bispecific platforms. Comparable as a small-cap antibody-focused oncology company with multiple clinical-stage assets.

Emerging players

• Pieris Pharmaceuticals: Clinical-stage biotech developing Anticalin-based therapeutics (engineered non-antibody scaffold proteins) in oncology and respiratory disease. Comparable as a small biotech using a proprietary protein scaffold discovery approach for therapeutic development.
• Werewolf Therapeutics: Clinical-stage US biotech developing conditionally activated therapeutics for cancer using proprietary PREDATOR platform. Comparable as a small oncology biotech with multiple preclinical/early-clinical candidates and platform approach.

Regional players

• Ryvu Therapeutics: Polish clinical-stage oncology biotech developing small-molecule therapies. Comparable as a fellow Polish biotech with similar headcount and clinical-stage profile, though focused on small molecules rather than biologics.
• Mabion: Polish biopharmaceutical company developing biosimilars and biologics manufacturing. Comparable as a Polish biotech with biological drug development focus, though Mabion is more focused on biosimilars/CDMO rather than novel antibody discovery.
• Selvita: Polish CRO and drug discovery company providing early-stage research services. Comparable as a Polish biotech ecosystem peer with overlapping scientific talent pool, though business model is more services-oriented.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pure Biologics